blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3670650

EP3670650 - CELL STRAIN FOR REDUCING PRODUCTION OF REPRODUCIBLE ADENOVIRUS, AND CONSTRUCTION METHOD AND USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.04.2023
Database last updated on 20.09.2024
FormerThe patent has been granted
Status updated on  06.05.2022
FormerGrant of patent is intended
Status updated on  08.02.2022
FormerExamination is in progress
Status updated on  06.11.2020
FormerRequest for examination was made
Status updated on  22.05.2020
FormerThe international publication has been made
Status updated on  09.03.2019
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Cansino Biologics Inc.
401-420, Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
[2020/26]
Inventor(s)01 / ZHU, Tao
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
02 / CUI, Haiyan
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
03 / CHEN, Weiwei
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
04 / DUAN, Lei
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
05 / LI, Junqiang
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
06 / MA, Jin
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
07 / XIN, Chunlin
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
08 / SHAO, Zhongqi
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
09 / YU, Xuefeng
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
10 / MAO, Helen Huihua
401-420 Floor 4
Biomedical Park of West Zone
185 South Avenue
TEDA West District
Tianjin 300457 / CN
 [2020/26]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2022/23]Murgitroyd & Company
Murgitroyd House
165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2020/26]Hanna Moore + Curley
Garryard House
25/26 Earlsfort Terrace
Dublin 2, D02 PX51 / IE
Application number, filing date18851666.029.08.2018
[2020/26]
WO2018CN102882
Priority number, dateCN20171077803201.09.2017         Original published format: CN201710778032
[2020/26]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019042307
Date:07.03.2019
Language:ZH
[2019/10]
Type: A1 Application with search report 
No.:EP3670650
Date:24.06.2020
Language:EN
[2020/26]
Type: B1 Patent specification 
No.:EP3670650
Date:08.06.2022
Language:EN
[2022/23]
Search report(s)International search report - published on:CN07.03.2019
(Supplementary) European search report - dispatched on:EP09.06.2020
ClassificationIPC:C12N5/10, C12N15/85, C12N15/90, C12N7/00, C12R1/93
[2020/26]
CPC:
C12N15/86 (EP,US); A61K39/235 (US); C12N15/907 (EP);
C12N5/0686 (US); C12N7/00 (EP); C12N2310/20 (EP);
C12N2710/10343 (EP); C12N2710/10352 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/26]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:ZELLSTAMM ZUR REDUKTION DER PRODUKTION VON REPRODUZIERBAREM ADENOVIRUS, KONSTRUKTIONSVERFAHREN UND VERWENDUNG[2020/26]
English:CELL STRAIN FOR REDUCING PRODUCTION OF REPRODUCIBLE ADENOVIRUS, AND CONSTRUCTION METHOD AND USE[2020/26]
French:SOUCHE CELLULAIRE POUR RÉDUIRE LA PRODUCTION D'ADÉNOVIRUS REPRODUCTIBLE ET PROCÉDÉ DE CONSTRUCTION ET UTILISATION[2020/26]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase19.03.2020Translation filed 
19.03.2020National basic fee paid 
19.03.2020Search fee paid 
19.03.2020Designation fee(s) paid 
19.03.2020Examination fee paid 
Examination procedure19.03.2020Examination requested  [2020/26]
10.09.2020Amendment by applicant (claims and/or description)
10.11.2020Despatch of a communication from the examining division (Time limit: M04)
08.01.2021Reply to a communication from the examining division
18.02.2021Despatch of a communication from the examining division (Time limit: M04)
02.06.2021Reply to a communication from the examining division
13.07.2021Despatch of a communication from the examining division (Time limit: M04)
29.10.2021Reply to a communication from the examining division
09.02.2022Communication of intention to grant the patent
02.05.2022Fee for grant paid
02.05.2022Fee for publishing/printing paid
02.05.2022Receipt of the translation of the claim(s)
Opposition(s)10.03.2023No opposition filed within time limit [2023/20]
Fees paidRenewal fee
19.03.2020Renewal fee patent year 03
23.07.2021Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.08.2018
AL08.06.2022
AT08.06.2022
CY08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
IT08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
MK08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
TR08.06.2022
IE29.08.2022
LU29.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
[2024/29]
Former [2024/27]HU29.08.2018
AL08.06.2022
AT08.06.2022
CY08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
IT08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
MK08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
IE29.08.2022
LU29.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2024/24]HU29.08.2018
AL08.06.2022
AT08.06.2022
CY08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
IT08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
IE29.08.2022
LU29.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2024/21]AL08.06.2022
AT08.06.2022
CY08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
IT08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
IE29.08.2022
LU29.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2024/11]AL08.06.2022
AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
IT08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
IE29.08.2022
LU29.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/42]AL08.06.2022
AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
IE29.08.2022
LU29.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/33]AL08.06.2022
AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
IE29.08.2022
LU29.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/25]AL08.06.2022
AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
LU29.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/21]AL08.06.2022
AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SK08.06.2022
SM08.06.2022
LU29.08.2022
CH31.08.2022
LI31.08.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/17]AL08.06.2022
AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/16]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/12]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/11]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
NL08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
PT10.10.2022
Former [2023/09]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
NL08.06.2022
RO08.06.2022
RS08.06.2022
SE08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
PT10.10.2022
Former [2023/07]AT08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
NL08.06.2022
RS08.06.2022
SE08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
Former [2023/02]ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
NL08.06.2022
RS08.06.2022
SE08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
Former [2022/50]ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
RS08.06.2022
SE08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
Former [2022/49]ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
SE08.06.2022
BG08.09.2022
NO08.09.2022
GR09.09.2022
Former [2022/47]ES08.06.2022
FI08.06.2022
LT08.06.2022
SE08.06.2022
NO08.09.2022
Documents cited:Search[XI]  - KOVESDI IMRE ET AL, "Adenoviral producer cells", VIRUSES, MDPI, CH, (20100816), vol. 2, no. 8, doi:10.3390/V2081681, ISSN 1999-4915, pages 1681 - 1703, XP008152094 [X] 1,2,6-15 * page 1681 - page 1703 * [I] 3-5

DOI:   http://dx.doi.org/10.3390/v2081681
 [XI]  - D. STONE ET AL, "Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector", JOURNAL OF VIROLOGY, (20050415), vol. 79, no. 8, doi:10.1128/JVI.79.8.5090-5104.2005, ISSN 0022-538X, pages 5090 - 5104, XP055052797 [X] 1,2,6-15 * page 5090 - page 5104 * [I] 3-5

DOI:   http://dx.doi.org/10.1128/JVI.79.8.5090-5104.2005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.